Roche Says Breast-Cancer Drug Shows Potential to Become Standard-Of-Care

• Roche announced that its breast-cancer drug, Giredestrant, has demonstrated a 30% reduction in the risk of disease recurrence or death compared to standard endocrine therapy. This finding suggests a significant advancement in treatment options for breast cancer patients.
• The positive results from Giredestrant could position Roche to potentially establish this drug as a new standard-of-care in breast cancer treatment, enhancing its portfolio and reinforcing its commitment to innovative healthcare solutions.

— via World Pulse Now AI Editorial System